Scots warned as ‘Dracula' horseflies with ‘most painful bite' worse than MIDGES on the rise
STAY SAFE Scots warned as 'Dracula' horseflies with 'most painful bite' worse than MIDGES on the rise
DRACULA horseflies with 'excruciating' bites are on the rise as temperatures soar in Scotland.
The flying vampire bugs can bite through clothes, tear through flesh and even fend off repellents.
Advertisement
1
A bite from a horsefly is often extremely painful and likely to be red and itchy
Wounds inflicted by horseflies might not even be fully treatable with current antibiotics.
Their painful bites can also spread harmful infections like cellulitis, which can trigger sepsis.
A bite from these silent bloodsuckers is often extremely painful, much more so than that of a tick or a midge.
Symptoms include redness, itchiness and minor swelling around the bite site.
Advertisement
However, bites can also trigger more serious symptoms like dizziness and weakness, shortness of breath, painful rashes or itchy pale pink skind around the eyes and lips.
Allergy sufferers are also at risk of experiencing anaphylaxis from insect bites.
And in some rare cases, horseflies can even pass on a bacterial infection called tularemia or 'rabbit fever' through their bite.
Horseflies have large eyes with blade-like mouths.
Advertisement
The female bloodsuckers rely on the high protein levels in blood to make eggs.
They are often found near large bodies of water and in Mediterranean countries, but this summer's hot weather and occasional downpours have lured them over to the UK.
Stuff of nightmares' as thousands of midges form 'insect tornado' in skin-crawling video
What does a horsefly bite look like?
If bitten by a horsefly, you will notice your skin turning red, becoming itchy and sometimes seeing raised bumps.
It will be very painful, and a raised rash could also be visible.
Advertisement
It will be obvious you have been bitten almost immediately due to the pain, and the red, itchy and swollen bumps developing within minutes of being bitten.
How to treat bites
If bitten, it is important to cleanse the area immediately.
You can use an antiseptic spray or wash with clean, warm water and soap to lower infection risk.
To treat at home, the NHS recommends you:
Advertisement
put an ice pack wrapped in a cloth or a clean cloth soaked in cold water on the bite or sting for at least 20 minutes, if it's swollen
keep the area raised if you can
take painkillers such as paracetamol or ibuprofen if the sting is painful
use antihistamines to relieve any itching
use a hydrocortisone cream to reduce itching and swelling
You can speak to pharmacist for advice too.
Whatever you do, do not scratch it, or use homemade remedies on it.
A horsefly bite will usually heal on its own, but there are some warning signs indicating it has become worse and you may need to see your GP.
According to Healthline, this can include noticing a foul odour or seeing excessive puss coming from the bite.
Advertisement
The health site added that if experiencing 'difficulty breathing, a rash that spreads or worsening pain, you should seek medical attention'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Rhyl Journal
2 hours ago
- Rhyl Journal
Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'
North Wales Chronicle
2 hours ago
- North Wales Chronicle
Record number of NHS operations given in private hospitals
Data from the Independent Healthcare Providers Network (IHPN) show that private hospitals delivered the equivalent of 2,859 NHS procedures every working day in April – an increase of over 60% compared to the same month in 2019. It said that almost one in five NHS operations in England are carried out in private hospitals and clinics. Overall, the independent sector is delivering 10% of all NHS planned care, up from 8% before the Covid-19 pandemic, the IHPN said. The IHPN also said that the number of referrals it had received has also reached a record high – with private providers receiving 7,162 referrals each working day in April. Official NHS data show that the waiting list for routine hospital treatment in England has fallen to its lowest level for two years. An estimated 7.39 million treatments were waiting to be carried out at the end of April, relating to 6.23 million patients – down from 7.42 million treatments and 6.25 million patients at the end of March. The Government has set out plans to send more patients for treatment in private hospitals to slash waiting lists. David Hare, chief executive of the IHPN, said: 'This latest data shows the independent sector's increasingly pivotal role in delivering frontline NHS care – delivering record levels of NHS care which will be instrumental in helping the Government to meet their key milestone to ensure 92% of patients are treated within 18 weeks by the end of this Parliament. 'While this is a clear sign of welcome progress in tackling NHS waiting lists, the sector is committed to building on this already impressive achievement and will be working with the Government to ensure the principles contained in the recent NHS and Independent Sector Partnership Agreement are fully embedded – enabling patients to have a greater choice over their care so they can get the treatment they need, when they need it.'
North Wales Chronicle
2 hours ago
- North Wales Chronicle
Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'
